Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015 (2015), Article ID 294303, 12 pages
http://dx.doi.org/10.1155/2015/294303
Review Article

Increased Oxidative Stress as a Selective Anticancer Therapy

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xian Lie Nan Road, Guangzhou 510060, China

Received 30 September 2014; Accepted 11 February 2015

Academic Editor: Elisa Giannoni

Copyright © 2015 Jiahui Liu and Zhichong Wang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. C. Gupta, D. Hevia, S. Patchva, B. Park, W. Koh, and B. B. Aggarwal, “Upsides and downsides of reactive oxygen species for Cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy,” Antioxidants and Redox Signaling, vol. 16, no. 11, pp. 1295–1322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. H. Burdon and C. Rice-Evans, “Free radicals and the regulation of mammalian cell proliferation,” Free Radical Research Communications, vol. 6, no. 6, pp. 345–358, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Storz and J. A. Imlay, “Oxidative stress,” Current Opinion in Microbiology, vol. 2, no. 2, pp. 188–194, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. R. H. Burdon, “Superoxide and hydrogen peroxide in relation to mammalian cell proliferation,” Free Radical Biology and Medicine, vol. 18, no. 4, pp. 775–794, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994. View at Publisher · View at Google Scholar · View at Scopus
  7. L. V. Nguyen, R. Vanner, P. Dirks, and C. J. Eaves, “Cancer stem cells: an evolving concept,” Nature Reviews Cancer, vol. 12, no. 2, pp. 133–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Li, D. Kong, A. Ahmad, B. Bao, and F. H. Sarkar, “Pancreatic cancer stem cells: emerging target for designing novel therapy,” Cancer Letters, vol. 338, no. 1, pp. 94–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. S. Koeneman, “Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype,” Urologic Oncology: Seminars and Original Investigations, vol. 24, no. 2, pp. 119–121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Economopoulou, V. G. Kaklamani, and K. Siziopikou, “The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies,” Oncologist, vol. 17, no. 11, pp. 1394–1401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. P. B. Gupta, C. L. Chaffer, and R. A. Weinberg, “Cancer stem cells: mirage or reality?” Nature Medicine, vol. 15, no. 9, pp. 1010–1012, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. F. Clarke and M. Fuller, “Stem cells and cancer: two faces of eve,” Cell, vol. 124, no. 6, pp. 1111–1115, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Shackleton, E. Quintana, E. R. Fearon, and S. J. Morrison, “Heterogeneity in cancer: cancer stem cells versus clonal evolution,” Cell, vol. 138, no. 5, pp. 822–829, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Zhao, D. Y. Alakhova, and A. V. Kabanov, “Can nanomedicines kill cancer stem cells?” Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1763–1783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. S. Balaban, S. Nemoto, and T. Finkel, “Mitochondria, oxidants, and aging,” Cell, vol. 120, no. 4, pp. 483–495, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Chance, H. Sies, and A. Boveris, “Hydroperoxide metabolism in mammalian organs,” Physiological Reviews, vol. 59, no. 3, pp. 527–605, 1979. View at Google Scholar · View at Scopus
  20. S. Pervaiz, R. Taneja, and S. Ghaffari, “Oxidative stress regulation of stem and progenitor cells,” Antioxidants & Redox Signaling, vol. 11, no. 11, pp. 2777–2789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Cohen and P. Hochstein, “Glutathione peroxidase: the primary agent for the elimination of hydrogen peroxide in erythrocytes,” Biochemistry, vol. 2, no. 6, pp. 1420–1428, 1963. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Hofmann, H. J. Hecht, and L. Flohé, “Peroxiredoxins,” Biological Chemistry, vol. 383, no. 3-4, pp. 347–364, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Michiels, M. Raes, O. Toussaint, and J. Remacle, “Importance of SE-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress,” Free Radical Biology and Medicine, vol. 17, no. 3, pp. 235–248, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Shi, Y. Zhang, J. Zheng, and J. Pan, “Reactive oxygen species in cancer stem cells,” Antioxidants and Redox Signaling, vol. 16, no. 11, pp. 1215–1228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Halliwell, “Free radicals and antioxidants: updating a personal view,” Nutrition Reviews, vol. 70, no. 5, pp. 257–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Dröge, “Free radicals in the physiological control of cell function,” Physiological Reviews, vol. 82, no. 1, pp. 47–95, 2002. View at Google Scholar · View at Scopus
  27. L. Raj, T. Ide, A. U. Gurkar et al., “Selective killing of cancer cells by a small molecule targeting the stress response to ROS,” Nature, vol. 475, no. 7355, pp. 231–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. X. Chen and S. Pervaiz, “Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells,” Cell Death and Differentiation, vol. 14, no. 9, pp. 1617–1627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Sattler, T. Winkler, S. Verma et al., “Hematopoietic growth factors signal through the formation of reactive oxygen species,” Blood, vol. 93, no. 9, pp. 2928–2935, 1999. View at Google Scholar · View at Scopus
  30. M.-V. Clément and I. Stamenkovic, “Superoxide anion is a natural inhibitor of FAS-mediated cell death,” The EMBO Journal, vol. 15, no. 2, pp. 216–225, 1996. View at Google Scholar · View at Scopus
  31. G. Achanta, R. Sasaki, L. Feng et al., “Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol γ,” The EMBO Journal, vol. 24, no. 19, pp. 3482–3492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Haghdoost, S. Czene, I. Näslund, S. Skog, and M. Harms-Ringdahl, “Extracellular 8-oxo-dG as a sensitive parameter for oxidative stress in vivo and in vitro,” Free Radical Research, vol. 39, no. 2, pp. 153–162, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Pan, M. She, Z.-X. Xu, L. Sun, and S.-C. J. Yeung, “Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells,” Cancer Research, vol. 65, no. 9, pp. 3671–3681, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. R. L. Wiseman, K.-T. Chin, C. M. Haynes et al., “Thioredoxin-related protein 32 is an arsenite-regulated thiol reductase of the proteasome 19 S particle,” The Journal of Biological Chemistry, vol. 284, no. 22, pp. 15233–15245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Nishikawa, “Reactive oxygen species in tumor metastasis,” Cancer Letters, vol. 266, no. 1, pp. 53–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. C. C. Winterbourn, “Reconciling the chemistry and biology of reactive oxygen species,” Nature Chemical Biology, vol. 4, no. 5, pp. 278–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. M. S. Cooke, M. D. Evans, M. Dizdaroglu, and J. Lunec, “Oxidative DNA damage: mechanisms, mutation, and disease,” The FASEB Journal, vol. 17, no. 10, pp. 1195–1214, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. L. J. Marnett, “Oxyradicals and DNA damage,” Carcinogenesis, vol. 21, no. 3, pp. 361–370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Rehman, “Empowering self-renewal and differentiation: the role of mitochondria in stem cells,” Journal of Molecular Medicine, vol. 88, no. 10, pp. 981–986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. D. L. Folmes, P. P. Dzeja, T. J. Nelson, and A. Terzic, “Metabolic plasticity in stem cell homeostasis and differentiation,” Cell Stem Cell, vol. 11, no. 5, pp. 596–606, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Lonergan, C. Brenner, and B. Bavister, “Differentiation-related changes in mitochondrial properties as indicators of stem cell competence,” Journal of Cellular Physiology, vol. 208, no. 1, pp. 149–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. V. Sosa, T. Moliné, R. Somoza, R. Paciucci, H. Kondoh, and M. E. LLeonart, “Oxidative stress and cancer: an overview,” Ageing Research Reviews, vol. 12, no. 1, pp. 376–390, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Diehn, R. W. Cho, N. A. Lobo et al., “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” Nature, vol. 458, no. 7239, pp. 780–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. L. S. Piao, W. Hur, T.-K. Kim et al., “CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma,” Cancer Letters, vol. 315, no. 2, pp. 129–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. X.-Q. Ye, G.-H. Wang, G.-J. Huang, X.-W. Bian, G.-S. Qian, and S.-C. Yu, “Heterogeneity of mitochondrial membrane potential: a novel tool to isolate and identify cancer stem cells from a tumor mass?” Stem Cell Reviews and Reports, vol. 7, no. 1, pp. 153–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. X.-Q. Ye, Q. Li, G.-H. Wang et al., “Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells,” International Journal of Cancer, vol. 129, no. 4, pp. 820–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Ishimoto, O. Nagano, T. Yae et al., “CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc and thereby promotes tumor growth,” Cancer Cell, vol. 19, no. 3, pp. 387–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Heddleston, Z. Li, J. D. Lathia, S. Bao, A. B. Hjelmeland, and J. N. Rich, “Hypoxia inducible factors in cancer stem cells,” British Journal of Cancer, vol. 102, no. 5, pp. 789–795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Ye, D. Wu, P. Wu, Z. Chen, and J. Huang, “The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment,” Tumor Biology, vol. 35, no. 5, pp. 3945–3951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Louie, S. Nik, J.-S. Chen et al., “Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation,” Breast Cancer Research, vol. 12, no. 6, article R94, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. V. K. Bhaskara, I. Mohanam, J. S. Rao, and S. Mohanam, “Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells,” PLoS ONE, vol. 7, no. 2, Article ID e30905, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Li, C. Zhou, L. Xu, and H. Xiao, “Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study,” International Journal of Medical Sciences, vol. 10, no. 4, pp. 399–407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Wei, A. Wu, L.-Y. Kong et al., “Hypoxia potentiates glioma-mediated immunosuppression,” PLoS ONE, vol. 6, no. 1, Article ID e16195, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Feig, A. Gopinathan, A. Neesse, D. S. Chan, N. Cook, and D. A. Tuveson, “The pancreas cancer microenvironment,” Clinical Cancer Research, vol. 18, no. 16, pp. 4266–4276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Pouysségur, F. Dayan, and N. M. Mazure, “Hypoxia signalling in cancer and approaches to enforce tumour regression,” Nature, vol. 441, no. 7092, pp. 437–443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. J. A. Bertout, S. A. Patel, and M. C. Simon, “The impact of O2 availability on human cancer,” Nature Reviews Cancer, vol. 8, no. 12, pp. 967–975, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Yuan, J. Nanduri, S. Khan, G. L. Semenza, and N. R. Prabhakar, “Induction of HIF-alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR,” Journal of Cellular Physiology, vol. 217, no. 3, pp. 674–685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Klimova and N. S. Chandel, “Mitochondrial complex III regulates hypoxic activation of HIF,” Cell Death and Differentiation, vol. 15, no. 4, pp. 660–666, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. N. Rohwer and T. Cramer, “Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways,” Drug Resistance Updates, vol. 14, no. 3, pp. 191–201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Zhao, Y. Zhu, A. Morinibu et al., “HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs,” Scientific Reports, vol. 4, article 3793, 2014. View at Publisher · View at Google Scholar
  61. J. A. Bertout, A. J. Majmundar, J. D. Gordan et al., “HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14391–14396, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. J. D. Gordan, P. Lal, V. R. Dondeti et al., “HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma,” Cancer Cell, vol. 14, no. 6, pp. 435–446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Scortegagna, K. Ding, Y. Oktay et al., “Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice,” Nature Genetics, vol. 35, no. 4, pp. 331–340, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Holmquist-Mengelbier, E. Fredlund, T. Löfstedt et al., “Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype,” Cancer Cell, vol. 10, no. 5, pp. 413–423, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Li, S. Bao, Q. Wu et al., “Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells,” Cancer Cell, vol. 15, no. 6, pp. 501–513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Iida, M. Suzuki, R. Goitsuka, and H. Ueno, “Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2,” International Journal of Oncology, vol. 40, no. 1, pp. 71–79, 2012. View at Google Scholar
  67. M. Y. Koh and G. Powis, “Passing the baton: the HIF switch,” Trends in Biochemical Sciences, vol. 37, no. 9, pp. 364–372, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Y. Koh, R. Lemos Jr., X. Liu, and G. Powis, “The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion,” Cancer Research, vol. 71, no. 11, pp. 4015–4027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Branco-Price, N. Zhang, M. Schnelle et al., “Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success,” Cancer Cell, vol. 21, no. 1, pp. 52–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. H. E. Lee, J. H. Kim, Y. J. Kim et al., “An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer,” British Journal of Cancer, vol. 104, no. 11, pp. 1730–1738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. C. L. Chaffer, I. Brueckmann, C. Scheel et al., “Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 19, pp. 7950–7955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Odoux, H. Fohrer, T. Hoppo et al., “A stochastic model for cancer stem cell origin in metastatic colon cancer,” Cancer Research, vol. 68, no. 17, pp. 6932–6941, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. I. Malanchi, A. Santamaria-Martínez, E. Susanto et al., “Interactions between cancer stem cells and their niche govern metastatic colonization,” Nature, vol. 481, no. 7379, pp. 85–91, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Scheel, E. N. Eaton, S. H.-J. Li et al., “Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast,” Cell, vol. 145, no. 6, pp. 926–940, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Driessens, B. Beck, A. Caauwe, B. D. Simons, and C. Blanpain, “Defining the mode of tumour growth by clonal analysis,” Nature, vol. 488, no. 7412, pp. 527–530, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Mathieu, Z. Zhang, W. Zhou et al., “HIF induces human embryonic stem cell markers in cancer cells,” Cancer Research, vol. 71, no. 13, pp. 4640–4652, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Krishnamachary, M.-F. Penet, S. Nimmagadda et al., “Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer,” PLoS ONE, vol. 7, no. 8, Article ID e44078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. N. Platet, S. Y. Liu, M. E. Atifi et al., “Influence of oxygen tension on CD133 phenotype in human glioma cell cultures,” Cancer Letters, vol. 258, no. 2, pp. 286–290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. F. M. Gabhann and A. S. Popel, “Systems biology of vascular endothelial growth factors,” Microcirculation, vol. 15, no. 8, pp. 715–738, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. J. M. Heddleston, Z. Li, R. E. McLendon, A. B. Hjelmeland, and J. N. Rich, “The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype,” Cell Cycle, vol. 8, no. 20, pp. 3274–3284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Schepers, D. van Gosliga, A. T. J. Wierenga, B. J. L. Eggen, J. J. Schuringa, and E. Vellenga, “STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells,” Blood, vol. 110, no. 8, pp. 2880–2888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Stingl, P. Eirew, I. Ricketson et al., “Purification and unique properties of mammary epithelial stem cells,” Nature, vol. 439, no. 7079, pp. 993–997, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland, “Prospective identification of tumorigenic prostate cancer stem cells,” Cancer Research, vol. 65, no. 23, pp. 10946–10951, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of human brain tumour initiating cells,” Nature, vol. 432, no. 7015, pp. 396–401, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. W. Xu, B. G. Debeb, L. Lacerda, J. Li, and W. A. Woodward, “Tetrandrine, a compound common in Chinese traditional medicine, preferentially kills breast cancer tumor initiating cells (TICs) in vitro,” Cancers, vol. 3, no. 2, pp. 2274–2285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. N. E. Bhola, J. M. Balko, T. C. Dugger et al., “TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer,” The Journal of Clinical Investigation, vol. 123, no. 3, pp. 1348–1358, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Natsuizaka, H. Kinugasa, S. Kagawa et al., “IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment,” The American Journal of Cancer Research, vol. 4, no. 1, pp. 29–41, 2014. View at Google Scholar
  88. Y. Mishima, Y. Matsumoto-Mishima, Y. Terui et al., “Leukemic cell-surface CD13/aminopeptidase N and resistance to apoptosis mediated by endothelial cells,” Journal of the National Cancer Institute, vol. 94, no. 13, pp. 1020–1028, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. H. M. Kim, N. Haraguchi, H. Ishii et al., “Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon,” Annals of Surgical Oncology, vol. 19, no. 3, supplement, pp. S539–S548, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. N. Haraguchi, H. Ishii, K. Mimori et al., “CD13 is a therapeutic target in human liver cancer stem cells,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3326–3339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. L. E. Ailles and I. L. Weissman, “Cancer stem cells in solid tumors,” Current Opinion in Biotechnology, vol. 18, no. 5, pp. 460–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Zöller, “CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?” Nature Reviews Cancer, vol. 11, no. 4, pp. 254–267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. N. A. Lobo, Y. Shimono, D. Qian, and M. F. Clarke, “The biology of cancer stem cells,” Annual Review of Cell and Developmental Biology, vol. 23, no. 1, pp. 675–699, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983–3988, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. M. E. Prince, R. Sivanandan, A. Kaczorowski et al., “Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 973–978, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. P. C. Hermann, S. L. Huber, T. Herrler et al., “Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer,” Cell Stem Cell, vol. 1, no. 3, pp. 313–323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Dalerba, S. J. Dylla, I.-K. Park et al., “Phenotypic characterization of human colorectal cancer stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10158–10163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Ishimoto, H. Sugihara, M. Watanabe et al., “Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation,” Carcinogenesis, vol. 35, no. 5, pp. 1003–1011, 2014. View at Publisher · View at Google Scholar
  99. O. Nagano, S. Okazaki, and H. Saya, “Redox regulation in stem-like cancer cells by CD44 variant isoforms,” Oncogene, vol. 32, no. 44, pp. 5191–5198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Bonnet and J. E. Dick, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–737, 1997. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Jin, K. J. Hope, Q. Zhai, F. Smadja-Joffe, and J. E. Dick, “Targeting of CD44 eradicates human acute myeloid leukemic stem cells,” Nature Medicine, vol. 12, no. 10, pp. 1167–1174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. L. Jin, E. M. Lee, H. S. Ramshaw et al., “Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells,” Cell Stem Cell, vol. 5, no. 1, pp. 31–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. R. Majeti, M. P. Chao, A. A. Alizadeh et al., “CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells,” Cell, vol. 138, no. 2, pp. 286–299, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. C. T. Jordan, D. Upchurch, S. J. Szilvassy et al., “The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stems cells,” Leukemia, vol. 14, no. 10, pp. 1777–1784, 2000. View at Publisher · View at Google Scholar · View at Scopus
  105. C. V. Cox, R. S. Evely, A. Oakhill, D. H. Pamphilon, N. J. Goulden, and A. Blair, “Characterization of acute lymphoblastic leukemia progenitor cells,” Blood, vol. 104, no. 9, pp. 2919–2925, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. M. Yang and J. W. Chang, “Bladder cancer initiating cells (BCICs) are among EMACD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells,” Cancer Investigation, vol. 26, no. 7, pp. 725–733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. X. He, L. Marchionni, D. E. Hansel et al., “Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma,” Stem Cells, vol. 27, no. 7, pp. 1487–1495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. K. S. Chan, I. Espinosa, M. Chao et al., “Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14016–14021, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome,” Cell Stem Cell, vol. 1, no. 5, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. J.-X. Xu, E. Morii, Y. Liu et al., “High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population,” Experimental Cell Research, vol. 313, no. 9, pp. 1877–1885, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. M. J. Meyer, J. M. Fleming, A. F. Lin, S. A. Hussnain, E. Ginsburg, and B. K. Vonderhaar, “CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer,” Cancer Research, vol. 70, no. 11, pp. 4624–4633, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. W.-M. Lin, U. Karsten, S. Goletz, R.-C. Cheng, and Y. Cao, “Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells,” International Journal of Experimental Pathology, vol. 92, no. 2, pp. 97–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. W. Gu, E. Yeo, N. McMillan, and C. Yu, “Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability,” Cancer Gene Therapy, vol. 18, no. 12, pp. 897–905, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. J. López, A. Poitevin, V. Mendoza-Martínez, C. Pérez-Plasencia, and A. García-Carrancá, “Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance,” BMC Cancer, vol. 12, article 48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identification and expansion of human colon-cancer-initiating cells,” Nature, vol. 445, no. 7123, pp. 111–115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Kemper, C. Grandela, and J. P. Medema, “Molecular identification and targeting of colorectal cancer stem cells.,” Oncotarget, vol. 1, no. 6, pp. 387–395, 2010. View at Google Scholar · View at Scopus
  117. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. E. H. Huang, M. J. Hynes, T. Zhang et al., “Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis,” Cancer Research, vol. 69, no. 8, pp. 3382–3389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. N. Barker, R. A. Ridgway, J. H. van Es et al., “Crypt stem cells as the cells-of-origin of intestinal cancer,” Nature, vol. 457, no. 7229, pp. 608–611, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. T. Okumura, S. Tsunoda, Y. Mori et al., “The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma,” Clinical Cancer Research, vol. 12, no. 17, pp. 5096–5103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. J. K. Smit, H. Faber, M. Niemantsverdriet et al., “Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers,” Radiotherapy and Oncology, vol. 107, no. 3, pp. 434–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. K. H. Tang, Y. D. Dai, M. Tong et al., “A CD90+ tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer,” Cancer Research, vol. 73, no. 7, pp. 2322–2332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  123. C. Shi, R. Tian, M. Wang et al., “CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma,” Cancer Biology & Therapy, vol. 10, no. 11, pp. 1182–1190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Wang, J. Xiao, J. Jiang, and R. Qin, “CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells,” International Journal of Cancer, vol. 128, no. 8, pp. 1996–1997, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. T. Chen, K. Yang, J. Yu et al., “Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients,” Cell Research, vol. 22, no. 1, pp. 248–258, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Jiang, Y. Zhang, S. Chuai et al., “Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype,” Oncogene, vol. 31, no. 6, pp. 671–682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Christensen, C. Aaberg-Jessen, C. Andersen, D. Goplen, R. Bjerkvig, and B. W. Kristensen, “Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium,” Neurosurgery, vol. 66, no. 5, pp. 933–947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. K. Mishima, Y. Kato, M. K. Kaneko, R. Nishikawa, T. Hirose, and M. Matsutani, “Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression,” Acta Neuropathologica, vol. 111, no. 5, pp. 483–488, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. M. J. Son, K. Woolard, D.-H. Nam, J. Lee, and H. A. Fine, “SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma,” Cell Stem Cell, vol. 4, no. 5, pp. 440–452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. A. Tchoghandjian, N. Baeza, C. Colin et al., “A2B5 cells from human glioblastoma have cancer stem cell properties,” Brain Pathology, vol. 20, no. 1, pp. 211–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  131. J. Anido, A. Sáez-Borderías, A. Gonzàlez-Juncà et al., “TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma,” Cancer Cell, vol. 18, no. 6, pp. 655–668, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. Y.-C. Chen, D.-T. Chen, Y.-W. Chen et al., “Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer,” Biochemical and Biophysical Research Communications, vol. 385, no. 3, pp. 307–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. Z. F. Yang, D. W. Ho, M. N. Ng et al., “Significance of CD90+ cancer stem cells in human liver cancer,” Cancer Cell, vol. 13, no. 2, pp. 153–166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. Z. Zhu, X. Hao, M. Yan et al., “Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma,” International Journal of Cancer, vol. 126, no. 9, pp. 2067–2078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  135. B. Terris, C. Cavard, and C. Perret, “EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma,” Journal of Hepatology, vol. 52, no. 2, pp. 280–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. O. Kimura, T. Takahashi, N. Ishii et al., “Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines,” Cancer Science, vol. 101, no. 10, pp. 2145–2155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. A. Eramo, F. Lotti, G. Sette et al., “Identification and expansion of the tumorigenic lung cancer stem cell population,” Cell Death and Differentiation, vol. 15, no. 3, pp. 504–514, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. E. L.-H. Leung, R. R. Fiscus, J. W. Tung et al., “Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties,” PLoS ONE, vol. 5, no. 11, Article ID e14062, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. C. D. Salcido, A. Larochelle, B. J. Taylor, C. E. Dunbar, and L. Varticovski, “Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer,” British Journal of Cancer, vol. 102, no. 11, pp. 1636–1644, 2010. View at Publisher · View at Google Scholar · View at Scopus
  140. W. C. Zhang, N. Shyh-Chang, H. Yang et al., “Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis,” Cell, vol. 148, no. 1-2, pp. 259–272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. A. D. Boiko, O. V. Razorenova, M. van de Rijn et al., “Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271,” Nature, vol. 466, no. 7302, pp. 133–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. D. Fang, M. Herlyn, T. K. Nguyen et al., “A tumorigenic subpopulation with stem cell properties in melanomas,” Cancer Research, vol. 65, no. 20, pp. 9328–9337, 2005. View at Publisher · View at Google Scholar · View at Scopus
  143. E. Quintana, M. Shackleton, H. R. Foster et al., “Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized,” Cancer Cell, vol. 18, no. 5, pp. 510–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. A. Roesch, M. Fukunaga-Kalabis, E. C. Schmidt et al., “A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth,” Cell, vol. 141, no. 4, pp. 583–594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. T. Schatton, G. F. Murphy, N. Y. Frank et al., “Identification of cells initiating human melanomas,” Nature, vol. 451, no. 7176, pp. 345–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. J. Su, X.-H. Xu, Q. Huang et al., “Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line,” Archives of Medical Research, vol. 42, no. 1, pp. 15–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Wu, W. Luo, Q. Zhang et al., “Aldehyde dehydrogenase 1, a functional marker for identifying cancer stem cells in human nasopharyngeal carcinoma,” Cancer Letters, vol. 330, no. 2, pp. 181–189, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. H.-W. Zhuang, T.-T. Mo, W.-J. Hou et al., “Biological characteristics of CD133+ cells in nasopharyngeal carcinoma,” Oncology Reports, vol. 30, no. 1, pp. 57–63, 2013. View at Publisher · View at Google Scholar · View at Scopus
  149. Q. Zhang, S. Shi, Y. Yen, J. Brown, J. Q. Ta, and A. D. Le, “A subpopulation of CD133+ cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy,” Cancer Letters, vol. 289, no. 2, pp. 151–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. Z. Noto, T. Yoshida, M. Okabe et al., “CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics,” Oral Oncology, vol. 49, no. 8, pp. 787–795, 2013. View at Publisher · View at Google Scholar · View at Scopus
  151. C. P. Gibbs, V. G. Kukekov, J. D. Reith et al., “Stem-like cells in bone sarcomas: implications for tumorigenesis,” Neoplasia, vol. 7, no. 11, pp. 967–976, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. A. S. Adhikari, N. Agarwal, B. M. Wood et al., “CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance,” Cancer Research, vol. 70, no. 11, pp. 4602–4612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. R. Veselska, M. Hermanova, T. Loja et al., “Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines,” BMC Cancer, vol. 8, article 300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  154. V. Saini, C. D. Hose, A. Monks et al., “Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma,” PLoS ONE, vol. 7, no. 8, Article ID e41401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  155. M. D. Curley, V. A. Therrien, C. L. Cummings et al., “CD133 expression defines a tumor initiating cell population in primary human ovarian cancer,” Stem Cells, vol. 27, no. 12, pp. 2875–2883, 2009. View at Publisher · View at Google Scholar · View at Scopus
  156. S. Zhang, C. Balch, M. W. Chan et al., “Identification and characterization of ovarian cancer-initiating cells from primary human tumors,” Cancer Research, vol. 68, no. 11, pp. 4311–4320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. A. J. Ziebarth, S. Nowsheen, A. D. Steg et al., “Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer,” Clinical Cancer Research, vol. 19, no. 1, pp. 170–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  158. K. Meirelles, L. A. Benedict, D. Dombkowski et al., “Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2358–2363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. L. Luo, J. Zeng, B. Liang et al., “Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome,” Experimental and Molecular Pathology, vol. 91, no. 2, pp. 596–602, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. C. Li, C. J. Lee, and D. M. Simeone, “Identification of human pancreatic cancer stem cells,” in Cancer Stem Cells, J. S. Yu, Ed., vol. 568 of Methods in Molecular Biology, pp. 161–173, Humana Press, Clifton, NJ, USA, 2009. View at Google Scholar
  161. L. Xin, D. A. Lawson, and O. N. Witte, “The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6942–6947, 2005. View at Publisher · View at Google Scholar · View at Scopus
  162. R. E. Reiter, Z. Gu, T. Watabe et al., “Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 4, article 1735, 1998. View at Publisher · View at Google Scholar · View at Scopus
  163. M. A. Dall'Era, L. D. True, A. F. Siegel, M. P. Porter, T. M. Sherertz, and A. Y. Liu, “Differential expression of CD10 in prostate cancer and its clinical implication,” BMC Urology, vol. 7, article 3, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. A. M. Havens, Y. H. Jung, Y. X. Sun et al., “The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis,” BMC Cancer, vol. 6, article 195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  165. I. Malanchi, H. Peinado, D. Kassen et al., “Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling,” Nature, vol. 452, no. 7187, pp. 650–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Schober and E. Fuchs, “Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-β and integrin/focal adhesion kinase (FAK) signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 26, pp. 10544–10549, 2011. View at Publisher · View at Google Scholar · View at Scopus
  167. K. Shimada, S. Anai, T. Fujii, N. Tanaka, K. Fujimoto, and N. Konishi, “Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells,” The Journal of Pathology, vol. 231, no. 4, pp. 495–504, 2013. View at Publisher · View at Google Scholar · View at Scopus
  168. E. D. Lagadinou, A. Sach, K. Callahan et al., “BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells,” Cell Stem Cell, vol. 12, no. 3, pp. 329–341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  169. N. Wada, M. Zhan, Y. Hori, K. Honma, J.-I. Ikeda, and E. Morii, “Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line,” Laboratory Investigation, vol. 94, no. 1, pp. 79–88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  170. R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  171. C. Gorrini, I. S. Harris, and T. W. Mak, “Modulation of oxidative stress as an anticancer strategy,” Nature Reviews Drug Discovery, vol. 12, no. 12, pp. 931–947, 2013. View at Publisher · View at Google Scholar · View at Scopus
  172. K. Ito, R. Bernardi, A. Morotti et al., “PML targeting eradicates quiescent leukaemia-initiating cells,” Nature, vol. 453, no. 7198, pp. 1072–1078, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. T. Šimůnek, M. Štěrba, O. Popelová, M. Adamcová, R. Hrdina, and V. Gerši, “Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron,” Pharmacological Reports, vol. 61, no. 1, pp. 154–171, 2009. View at Publisher · View at Google Scholar · View at Scopus
  174. J. Alexandre, Y. Hu, W. Lu, H. Pelicano, and P. Huang, “Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species,” Cancer Research, vol. 67, no. 8, pp. 3512–3517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  175. Y. Jin, Z. Lu, K. Ding et al., “Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-κB pathway and generation of reactive oxygen species,” Cancer Research, vol. 70, no. 6, pp. 2516–2527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  176. T. Yoshida, S. Goto, M. Kawakatsu, Y. Urata, and T.-S. Li, “Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation,” Free Radical Research, vol. 46, no. 2, pp. 147–153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  177. J.-A. Losman, R. E. Looper, P. Koivunen et al., “(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible,” Science, vol. 340, no. 6127, pp. 1621–1625, 2013. View at Publisher · View at Google Scholar · View at Scopus
  178. F. Wang, J. Travins, B. DeLaBarre et al., “Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation,” Science, vol. 340, no. 6132, pp. 622–626, 2013. View at Publisher · View at Google Scholar · View at Scopus
  179. J. Zhu, X. Song, H.-P. Lin et al., “Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents,” Journal of the National Cancer Institute, vol. 94, no. 23, pp. 1745–1757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  180. O. W. Griffith, “Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis,” The Journal of Biological Chemistry, vol. 257, no. 22, pp. 13704–13712, 1982. View at Google Scholar · View at Scopus
  181. M. Lo, V. Ling, C. Low, Y. Z. Wang, and P. W. Gout, “Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer,” Current Oncology, vol. 17, no. 3, pp. 9–16, 2010. View at Google Scholar · View at Scopus
  182. P. W. Gout, A. R. Buckley, C. R. Simms, and N. Bruchovsky, “Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the Xc- cystine transporter: a new action for an old drug,” Leukemia, vol. 15, no. 10, pp. 1633–1640, 2001. View at Publisher · View at Google Scholar · View at Scopus
  183. A. J. Montero, C. M. Diaz-Montero, Y. E. Deutsch et al., “Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer,” Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 215–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. C. A. Belfi, S. Chatterjee, D. M. Gosky, S. J. Berger, and N. A. Berger, “Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation,” Biochemical and Biophysical Research Communications, vol. 257, no. 2, pp. 361–368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  185. R. Pieters, S. P. Hunger, J. Boos et al., “L-asparaginase treatment in acute lymphoblastic leukemia,” Cancer, vol. 117, no. 2, pp. 238–249, 2011. View at Publisher · View at Google Scholar · View at Scopus
  186. A. Le, A. N. Lane, M. Hamaker et al., “Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells,” Cell Metabolism, vol. 15, no. 1, pp. 110–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  187. C. Marzano, V. Gandin, A. Folda, G. Scutari, A. Bindoli, and M. P. Rigobello, “Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells,” Free Radical Biology and Medicine, vol. 42, no. 6, pp. 872–881, 2007. View at Publisher · View at Google Scholar · View at Scopus
  188. M. L. Guzman, R. M. Rossi, L. Karnischky et al., “The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells,” Blood, vol. 105, no. 11, pp. 4163–4169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  189. S. H. Kaufmann and W. C. Earnshaw, “Induction of apoptosis by cancer chemotherapy,” Experimental Cell Research, vol. 256, no. 1, pp. 42–49, 2000. View at Publisher · View at Google Scholar · View at Scopus
  190. K. A. Conklin, “Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness,” Integrative Cancer Therapies, vol. 3, no. 4, pp. 294–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  191. G. Barrera, “Oxidative stress and lipid peroxidation products in cancer progression and therapy,” ISRN Oncology, vol. 2012, Article ID 137289, 21 pages, 2012. View at Publisher · View at Google Scholar
  192. P. A. Riley, “Free radicals in biology: oxidative stress and the effects of ionizing radiation,” International Journal of Radiation Biology, vol. 65, no. 1, pp. 27–33, 1994. View at Publisher · View at Google Scholar · View at Scopus
  193. Y. Tateishi, E. Sasabe, E. Ueta, and T. Yamamoto, “Ionizing irradiation induces apoptotic damage of salivary gland acinar cells via NADPH oxidase 1-dependent superoxide generation,” Biochemical and Biophysical Research Communications, vol. 366, no. 2, pp. 301–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  194. T. Yamamori, H. Yasui, M. Yamazumi et al., “Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint,” Free Radical Biology and Medicine, vol. 53, no. 2, pp. 260–270, 2012. View at Publisher · View at Google Scholar · View at Scopus
  195. Y. Wang, L. Liu, S. K. Pazhanisamy, H. Li, A. Meng, and D. Zhou, “Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells,” Free Radical Biology and Medicine, vol. 48, no. 2, pp. 348–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  196. S. Bao, Q. Wu, R. E. McLendon et al., “Glioma stem cells promote radioresistance by preferential activation of the DNA damage response,” Nature, vol. 444, no. 7120, pp. 756–760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  197. M. Ropolo, A. Daga, F. Griffero et al., “Comparative analysis of DNA repair in stem and nonstem glioma cell cultures,” Molecular Cancer Research, vol. 7, no. 3, pp. 383–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  198. A. M. McCord, M. Jamal, E. S. Williams, K. Camphausen, and P. J. Tofilon, “CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines,” Clinical Cancer Research, vol. 15, no. 16, pp. 5145–5153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  199. S.-Y. Kim, J. G. Rhee, X. Song, E. V. Prochownik, D. R. Spitz, and Y. J. Lee, “Breast cancer stem cell-like cells are more sensitive to ionizing radiation than non-stem cells: role of ATM,” PLoS ONE, vol. 7, no. 11, Article ID e50423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  200. D.-J. Tai, W.-S. Jin, C.-S. Wu et al., “Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells,” Experimental and Therapeutic Medicine, vol. 4, no. 2, pp. 291–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  201. A. Sobhakumari, L. Love-Homan, E. V. M. Fletcher et al., “Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism,” PLoS ONE, vol. 7, no. 10, Article ID e48175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  202. H.-W. Chiu, Y.-A. Chen, S.-Y. Ho, and Y.-J. Wang, “Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells,” PLoS ONE, vol. 7, no. 2, Article ID e31579, 2012. View at Publisher · View at Google Scholar · View at Scopus
  203. L.-C. Lin, C.-T. Yeh, C.-C. Kuo et al., “Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function,” Journal of Agricultural and Food Chemistry, vol. 60, no. 28, pp. 7031–7039, 2012. View at Publisher · View at Google Scholar · View at Scopus
  204. P. Kovacic and J. D. Jacintho, “Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer,” Current Medicinal Chemistry, vol. 8, no. 7, pp. 773–796, 2001. View at Publisher · View at Google Scholar · View at Scopus
  205. K. I. Block, A. C. Koch, M. N. Mead, P. K. Tothy, R. A. Newman, and C. Gyllenhaal, “Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials,” International Journal of Cancer, vol. 123, no. 6, pp. 1227–1239, 2008. View at Google Scholar
  206. W. Zhang, X.-O. Shu, H. Li et al., “Vitamin intake and liver cancer risk: a report from two cohort studies in China,” Journal of the National Cancer Institute, vol. 104, no. 15, pp. 1174–1182, 2012. View at Publisher · View at Google Scholar · View at Scopus
  207. G. S. Omenn, G. E. Goodman, M. D. Thornquist et al., “Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease,” The New England Journal of Medicine, vol. 334, no. 18, pp. 1150–1155, 1996. View at Publisher · View at Google Scholar · View at Scopus
  208. J. Liu, X. Gu, D. Robbins et al., “Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model,” PLoS ONE, vol. 4, no. 4, Article ID e5284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  209. Y. S. Kim, W. Farrar, N. H. Colburn, and J. A. Milner, “Cancer stem cells: potential target for bioactive food components,” The Journal of Nutritional Biochemistry, vol. 23, no. 7, pp. 691–698, 2012. View at Publisher · View at Google Scholar · View at Scopus